

Can We Make Cancer Nonlethal? | Reed Jobs & Matt Bettonville of Yosemite
Sep 29, 2025
Reed Jobs, an investor leading Yosemite, is driven by a personal mission to make cancer non-lethal after losing his father to the disease. Joined by Matt Bettonville, they discuss the need for affordable cancer drugs and the surprising effectiveness of digital health tools in improving survival rates. They explore the potential of synthetic control arms to reduce clinical trial costs and emphasize the critical importance of early detection. Reed and Matt also highlight the urgency of maintaining U.S. leadership in global healthcare innovation.
AI Snips
Chapters
Transcript
Episode notes
Personal Origin Story For Yosemite
- Reed Jobs describes his personal journey into cancer research after losing his father and working in labs since his teens.
- That origin drove him to create Yosemite to build companies that change cancer care delivery and outcomes.
Delivery Can Match Drug Impact
- Matt Bettonville highlights a digital symptom-monitoring intervention that improved overall survival more than most new drugs at ASCO.
- He argues delivery methods can be as impactful as novel therapeutics for patient survival.
Use System Fixes To Lower Drug Costs
- Reed Jobs urges changing the system that controls drug pricing and dissemination rather than only building drugs.
- He recommends creating system efficiencies like synthetic control arms to lower phase III costs and speed trials.